Opioid pharmacology sits at the intersection of neuroscience, clinical medicine, and public health. No drug class in the pharmacopoeia simultaneously offers such profound therapeutic value, the reliable, titratable relief of severe pain, and such serious potential for harm. A rigorous understanding of opioid receptor biology, endogenous ligand systems, and molecular mechanisms of action is not merely academic; it is the foundation upon which rational clinical prescribing, anticipation of adverse effects, and recognition of overdose are built. This module covers the receptor pharmacology of opioids from the molecular level through the systems level, establishing the mechanistic framework that the subsequent modules will translate into clinical practice.
The term "opioid" refers broadly to any substance, endogenous or exogenous, natural or synthetic, that binds to opioid receptors and produces morphine-like effects that are reversible by the antagonist naloxone.1 The older term "opiate" refers specifically to naturally occurring alkaloids derived from the opium poppy Papaver somniferum, principally morphine and codeine; this distinction is pharmacologically meaningful because it separates plant-derived compounds from the vast synthetic and semisynthetic agents that share receptor targets but differ structurally.1 Opium has been used medicinally for at least 3,500 years, with references in the Ebers Papyrus and Sumerian clay tablets. Morphine was isolated from opium in 1804 by Friedrich Sertürner, marking the beginning of alkaloid pharmacology.2 The development of the hypodermic needle in the mid-19th century and the subsequent widespread use of injectable morphine during the American Civil War generated the first well-documented epidemic of iatrogenic opioid dependence, demonstrating that the clinical and social risks of these compounds are not modern phenomena.2 The elucidation of stereospecific opioid binding sites by Pert and Snyder in 1973 opened the modern era of opioid receptor pharmacology and set the stage for identifying the endogenous ligand systems.2
Four major opioid receptor types have been characterized: mu (μ), kappa (κ), delta (δ), and the nociceptin/orphanin FQ receptor (nociceptin opioid peptide receptor (NOP), also termed opioid receptor-like 1 receptor (ORL1)).4 A fifth receptor, zeta (ζ), has been proposed based on opioid growth factor binding in peripheral tissues but remains incompletely characterized and is not a clinical target. The three classical receptors, μ, κ, and δ, are the primary targets of both endogenous opioid peptides and exogenous opioid drugs. All opioid receptors are class A G-protein-coupled receptors (GPCRs) belonging to the rhodopsin superfamily. They share a characteristic seven-transmembrane α-helical structure, an extracellular N-terminus, and an intracellular C-terminus that couples to heterotrimeric G-proteins, primarily of the Gi/Go family.4 The transmembrane domains form the orthosteric binding pocket, and conservation of key residues, particularly Asp147 in transmembrane domain 3, is critical for ligand recognition across all three classical receptor types.5 Crystal structures of μ, κ, and δ receptors have been resolved, enabling rational drug design aimed at receptor subtype selectivity and biased agonism.5
The μ-opioid receptor (MOR), encoded by the mu-opioid receptor gene (OPRM1) gene, is the primary mediator of the analgesic, euphoric, and respiratory depressant effects of clinically used opioids.4 It is distributed widely throughout the central and peripheral nervous systems: in the brain, high densities are found in the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), thalamus, limbic system (nucleus accumbens, amygdala), and brainstem respiratory centers; in the spinal cord, MOR is concentrated in laminae I and II (substantia gelatinosa) of the dorsal horn; peripherally, MOR is expressed on primary afferent sensory neurons, immune cells, and enteric neurons.6 OPRM1 exhibits extensive genetic polymorphism; the A118G variant (Asn40Asp) alters receptor-ligand binding affinity and has been associated with variable analgesic requirements and opioid use disorder risk in multiple clinical studies, though effect sizes are modest and clinical utility of genotyping remains limited.7
The κ-opioid receptor (KOR), encoded by kappa-opioid receptor gene (OPRK1), mediates spinal analgesia, sedation, dysphoria, and psychotomimetic effects.4 KOR activation produces a distinctly unpleasant subjective experience, anxiety, dysphoria, and hallucinosis, that limits the therapeutic utility of pure κ agonists. KOR is prominent in the spinal cord dorsal horn, limbic system, and hypothalamus, where it modulates neuroendocrine function. KOR agonism also produces diuresis through suppression of antidiuretic hormone release; this is a pharmacological effect exploited historically by agents such as ketocyclazocine. The δ-opioid receptor (DOR), encoded by delta-opioid receptor gene (OPRD1), contributes to analgesia (both supraspinal and spinal), modulation of mood, and enhancement of μ-receptor signaling through receptor heterodimerization.4 DOR agonists have shown antidepressant and anxiolytic properties in preclinical models, and selective DOR agonists are under investigation as analgesic and antidepressant candidates, though none is currently approved for clinical use. DOR expression is particularly dense in the limbic cortex, striatum, and olfactory tubercle.
The NOP receptor (nociceptin opioid peptide receptor), encoded by nociceptin opioid peptide receptor gene (OPRL1), binds nociceptin/orphanin FQ (N/orphanin FQ (OFQ)) and was cloned in 1994 based on homology with the classical opioid receptors.4 Despite structural similarity, NOP does not bind naloxone with meaningful affinity, and its activation produces complex, context-dependent effects: at supraspinal sites, N/OFQ can oppose opioid analgesia and impair fear memory extinction; at spinal sites, it can produce analgesia. NOP receptor pharmacology remains an active area of research; cebranopadol, a co-agonist at both NOP and MOR, is in late-stage clinical development for chronic pain.
The discovery of stereospecific opioid binding sites immediately implied the existence of endogenous ligands: the brain was unlikely to have evolved receptors solely for plant alkaloids. Hughes and Kosterlitz identified the first endogenous opioid peptides, the enkephalins, in 1975, opening the field of opioid peptide neuroscience.3 Three major precursor proteins give rise to the classical endogenous opioid peptides. Pro-opiomelanocortin (POMC) is expressed primarily in the anterior pituitary and in neurons of the arcuate nucleus of the hypothalamus. Post-translational processing of POMC yields β-endorphin, the most potent endogenous opioid peptide, as well as ACTH, α-melanocyte-stimulating hormone (MSH), and β-MSH.8 β-Endorphin has high affinity for both μ and δ receptors and is the principal mediator of stress-induced analgesia and the "runner's high" phenomenon. β-Endorphin is released into the cerebrospinal fluid and portal circulation during stress, exercise, and pain, functioning as both a neurotransmitter and a neuromodulator over a wide area.8
Proenkephalin (PENK) is widely expressed throughout the brain, spinal cord, adrenal medulla, and peripheral nervous system. Processing yields met-enkephalin and leu-enkephalin, pentapeptides with preferential affinity for δ receptors and modest μ receptor activity.8 Enkephalins function as short-range neurotransmitters modulating pain transmission in the dorsal horn, limbic function, and motor activity in the striatum. Met-enkephalin is co-released with catecholamines from the adrenal medulla under stress. Prodynorphin (PDYN) is processed to yield dynorphin A, dynorphin B, and α/β-neoendorphin, peptides with primary affinity for κ receptors.8 Dynorphins are expressed in the hypothalamus, hippocampus, spinal cord, and striatum. Dynorphin A, one of the most potent endogenous opioid peptides by molar activity, exerts complex analgesic and pronociceptive effects depending on the spinal level and concentration; at very high concentrations in the dorsal horn following injury, dynorphin A can paradoxically facilitate pain transmission through non-opioid N-methyl-D-aspartate (NMDA) receptor mechanisms, contributing to central sensitization.9
Pronociceptin/proorphanin is the precursor of nociceptin/orphanin FQ (N/orphanin FQ (OFQ)), a 17-amino-acid peptide that is the endogenous ligand for the nociceptin opioid peptide receptor (NOP) receptor.4 As noted, N/OFQ has complex and site-dependent effects on pain modulation and is not reversed by classical opioid antagonists. All endogenous opioid peptides share the N-terminal sequence Tyr-Gly-Gly-Phe (the opioid motif) followed by either Met or Leu, which is critical for receptor recognition.8 Endogenous opioids are rapidly degraded by peptidases including neprilysin (enkephalinase) and aminopeptidase N; inhibition of these enzymes has been explored therapeutically but has not yielded approved drugs due to complex effects on multiple peptide substrates.
Opioid receptors couple predominantly to pertussis toxin-sensitive Gi/Go proteins, producing three well-characterized downstream effects.5 First, Gi/Go activation inhibits adenylyl cyclase, reducing intracellular cyclic AMP (cAMP) levels. This decreases protein kinase A (PKA) activity and reduces phosphorylation of downstream targets including CREB (cAMP response element-binding protein), attenuating transcription of neuropeptides and other genes regulated by cAMP-dependent pathways.5 Acute inhibition of cAMP mediates many of the short-term physiological effects of opioids; chronic suppression and the subsequent rebound elevation of cAMP upon receptor removal underlies a key molecular mechanism of physical dependence and withdrawal. Second, activated Gβγ subunits directly couple to inwardly rectifying potassium channels (G-protein-coupled inwardly rectifying potassium channels (GIRK) channels, particularly Kir3.1/Kir3.2 heteromers in neurons), increasing K⁺ conductance.5 The resulting membrane hyperpolarization reduces neuronal excitability and depresses spontaneous and evoked action potential firing. This mechanism is central to both the analgesic and respiratory depressant effects of opioids; the degree to which supraspinal respiratory neurons are hyperpolarized relative to analgesic circuits determines the therapeutic index for respiratory depression.
Third, Gβγ subunits inhibit voltage-gated calcium channels (VGCCs), particularly N-type (Cav2.2) and P/Q-type (Cav2.1) channels.5 Since Ca2⁺ influx through VGCCs is required for neurotransmitter vesicle fusion, opioid-mediated Ca2⁺ channel inhibition reduces presynaptic neurotransmitter release, including glutamate, substance P, and calcitonin gene-related peptide (CGRP) from primary afferent terminals in the dorsal horn, contributing substantially to the analgesic effect. Presynaptic Ca2⁺ channel inhibition at nociceptive synapses is a principal mechanism by which spinal opioids suppress pain transmission.
Beyond Gi/Go signaling, opioid receptors also activate mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways through β-arrestin-2 scaffolding following receptor phosphorylation and internalization.5 This β-arrestin pathway has attracted major interest because it appears to mediate several adverse effects, respiratory depression, constipation, and possibly tolerance, relatively independently of the G-protein pathway that mediates analgesia. "Biased agonists" designed to preferentially activate Gi over β-arrestin-2 have been developed with the intent of producing analgesia with reduced adverse effects; oliceridine (TRV130), the first approved biased mu-opioid receptor (MOR) agonist, showed modest improvements in the therapeutic index in clinical trials, though the clinical significance of bias at the receptor level remains debated.10
Repeated or sustained opioid receptor activation initiates several regulatory processes that progressively attenuate receptor responsiveness.5 G-protein-coupled receptor kinases (GRKs), particularly G-protein-coupled receptor kinase 2 (GRK2) and G-protein-coupled receptor kinase 3 (GRK3), phosphorylate the activated receptor at intracellular serine and threonine residues, recruiting β-arrestin-1 and β-arrestin-2. β-Arrestin binding sterically uncouples the receptor from its G-protein, producing acute desensitization. β-Arrestin also serves as a scaffold for receptor internalization via clathrin-coated pits, leading to receptor endocytosis. Internalized receptors may be dephosphorylated and recycled to the membrane (resensitization) or targeted for lysosomal degradation (downregulation).5 Different opioid agonists promote receptor internalization to markedly different degrees. Morphine, despite being a potent mu-opioid receptor (MOR) agonist, is a poor promoter of MOR internalization relative to etorphine or D-Ala2-N-MePhe4-Gly-ol enkephalin (DAMGO), a synthetic full MOR agonist used in receptor research; this has been attributed to weak β-arrestin recruitment at physiologically relevant concentrations.5 The clinical significance is debated, but some investigators have proposed that morphine's poor internalization-resensitization cycling paradoxically promotes accumulation of desensitized surface receptors, contributing to its propensity to produce tolerance. By contrast, methadone's pharmacological and tolerance profiles differ substantially from morphine, in part due to different receptor internalization kinetics.
At the cellular level, tolerance develops through: (1) desensitization and downregulation of opioid receptors; (2) upregulation of adenylyl cyclase (superactivation), creating a cAMP rebound upon opioid discontinuation; (3) alterations in ion channel expression and function; and (4) synaptic plasticity changes in pain-modulating circuits including the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM).9 These cellular changes collectively produce the state of physical dependence, a neuroadaptation in which normal function requires ongoing opioid presence, while tolerance specifically describes the requirement for increasing doses to achieve the same effect. Dependence and addiction are distinct phenomena; the former is a pharmacological adaptation and the latter involves compulsive drug-seeking behavior driven by mesolimbic dopamine dysregulation.9
Opioids produce analgesia through actions at multiple anatomically distinct sites, and this multilevel architecture is directly exploited in clinical practice through intrathecal and epidural drug delivery.6 At supraspinal sites, the periaqueductal gray (PAG) is the most extensively studied opioid-sensitive structure mediating descending pain modulation. Opioid activation of mu-opioid receptor (MOR) in the PAG disinhibits output neurons that project to the rostral ventromedial medulla (RVM), which in turn activates descending noradrenergic (via locus coeruleus and A7 cell group) and serotonergic (via nucleus raphe magnus) pathways that suppress pain transmission in the spinal cord dorsal horn.6 This descending inhibitory system is normally engaged during stress-induced analgesia and can be pharmacologically amplified by opioids administered supraspinally. Additional supraspinal sites include the thalamus, amygdala (where opioids reduce the affective/emotional component of pain), and anterior cingulate cortex.
At the spinal cord, opioid receptors in the dorsal horn, particularly in laminae I and II, the superficial layers that receive primary afferent input, mediate a major component of opioid analgesia. The actions are both presynaptic and postsynaptic. Presynaptically, μ and δ receptor activation on primary afferent terminals (predominantly Aδ and C fiber nociceptors) inhibits Ca2⁺ channel-mediated neurotransmitter release, reducing glutamate, substance P, and calcitonin gene-related peptide (CGRP) release into the synaptic cleft.6 Postsynaptically, opioid activation of G-protein-coupled inwardly rectifying potassium channels (GIRK) channels in dorsal horn interneurons and projection neurons hyperpolarizes these cells, reducing their responsiveness to remaining afferent input. The clinical consequence is that intrathecal or epidural opioids can produce profound segmental analgesia at doses 100- to 1000-fold lower than required systemically, with correspondingly reduced systemic adverse effects; complete elimination is not achieved, since spinally administered opioids can still diffuse rostrally in the CSF to brainstem respiratory centers.
At peripheral sites, opioid receptors are expressed on the central and peripheral terminals of primary afferent neurons.6 Under normal conditions, peripheral MOR is largely inactive because the receptor is maintained in a low-affinity state and the blood-nerve barrier restricts access of exogenous opioids. During inflammation, however, several factors dramatically upregulate peripheral opioid analgesia: inflammatory mediators enhance opioid receptor coupling and translocation to the peripheral terminal; disruption of the perineural barrier increases opioid access; and locally released β-endorphin and enkephalins from immune cells can activate peripheral MOR to produce endogenous analgesia.6 This mechanism underpins the clinical utility of intra-articular morphine in post-arthroscopic pain management and provides a rationale for peripherally restricted opioid compounds as candidates for analgesia without CNS side effects.
The wide anatomical distribution of opioid receptors, particularly mu-opioid receptor (MOR), accounts for the extensive systemic pharmacology of opioid agonists that extends far beyond analgesia. In the CNS, MOR activation in limbic circuits, particularly nucleus accumbens and ventral tegmental area, produces euphoria through modulation of mesolimbic dopaminergic activity.9 Opioids disinhibit dopamine neurons in the ventral tegmental area (VTA) by suppressing inhibitory GABAergic interneurons, increasing dopamine release in the nucleus accumbens. This dopaminergic reward signal is the neurobiological substrate of opioid reinforcement and the initial driver of opioid use disorder. Analgesia and euphoria can be partially dissociated, and the development of analgesic compounds that preferentially engage pain-modulating pathways without strongly activating mesolimbic reward circuits is an active goal of opioid drug development.9
Respiratory depression results from MOR activation in brainstem respiratory control centers, primarily the pre-Bötzinger complex, the rhythmogenic network in the ventrolateral medulla responsible for generating the respiratory rhythm, as well as the nucleus of the solitary tract and peripheral chemoreceptors.11 Opioids reduce respiratory rate primarily, with tidal volume relatively preserved at lower doses; at higher doses, both rate and tidal volume are depressed, and at toxic concentrations, apnea occurs. The respiratory response to hypercapnia is blunted, with opioids shifting the CO2 response curve rightward and raising the apneic threshold, so the normal drive to breathe in response to rising PaCO2 is attenuated. Sleep significantly increases the risk of opioid-induced respiratory depression because the arousal response to hypercapnia is diminished during sleep, removing a critical safety mechanism.11
In the gastrointestinal system, MOR and δ receptor activation in enteric neurons reduces propulsive motility, increases tonic segmental contraction, prolongs intestinal transit, and decreases secretion.6 The net effect is opioid-induced constipation (OIC), which is the most common persistent adverse effect of chronic opioid therapy and, unlike analgesic tolerance, does not substantially diminish with continued use. Peripheral MOR in the gut is also responsible for nausea and vomiting (through actions on the area postrema, which lacks a blood-brain barrier), delayed gastric emptying, biliary tract spasm (through contraction of the sphincter of Oddi), and urinary retention (through increased urethral sphincter tone).6
Neuroendocrine effects of chronic MOR activation include suppression of the hypothalamic-pituitary-gonadal (HPG) axis through inhibition of gonadotropin-releasing hormone (GnRH) pulsatility, producing hypogonadotropic hypogonadism in both men and women; adrenal insufficiency through suppression of the HPA axis; and elevation of prolactin through inhibition of dopaminergic tone in the tuberoinfundibular pathway.12 These opioid-induced endocrinopathies are clinically underrecognized, particularly in patients on long-term opioid therapy for chronic pain, and can cause fatigue, sexual dysfunction, menstrual irregularities, osteoporosis, and depression; these symptoms are often misattributed to the underlying pain condition or to depression.12 Cardiovascular effects of opioids are generally modest in normovolemic patients. At therapeutic doses, most opioids cause mild bradycardia (vagotonic effect, most pronounced with remifentanil and alfentanil) and minimal blood pressure change. Morphine and meperidine can trigger histamine release from mast cells, causing vasodilation, flushing, and hypotension, particularly with rapid intravenous administration. Methadone uniquely prolongs the cardiac QTc interval through hERG channel blockade, creating risk for torsades de pointes, particularly at high doses and in the context of drug interactions that inhibit CYP3A4 (cytochrome P450 3A4) metabolism.13
No currently marketed opioid analgesic is perfectly selective for a single receptor type at clinically relevant concentrations. Morphine and most full agonists are primarily mu-opioid receptor (MOR)-selective but bind κ and δ receptors at higher concentrations. The degree of receptor selectivity determines the clinical profile and explains why different opioids, even at equianalgesic doses, can produce substantially different side effect burdens in individual patients.4 The concept of functional selectivity (biased agonism) has added further complexity: the same receptor can be activated in ways that differentially engage G-protein versus β-arrestin pathways depending on the ligand, potentially producing different balances of analgesic and adverse effects even at the same receptor subtype.10 Oliceridine exemplifies this principle clinically, though the magnitude of its safety advantage over morphine in published trials has been modest, and it remains a relatively restricted agent in current practice. Receptor heterodimerization adds another layer: μ and δ receptors can form heterodimers with distinct pharmacological properties, including altered ligand binding, G-protein coupling efficiency, and internalization kinetics.5 MOR-delta-opioid receptor (DOR) heterodimers have been proposed as a target that could be exploited therapeutically to produce analgesia with reduced tolerance development. Bivalent ligands designed to bridge MOR and DOR binding sites remain experimental.
Understanding receptor pharmacology directly informs key clinical decisions. The ceiling effect of buprenorphine for respiratory depression (but not for analgesia, which continues to increase with dose up to very high levels) stems from its partial agonist behavior at MOR, receptor occupancy without full intrinsic efficacy, and from its extremely high receptor affinity (Ki ~0.1–1 nM) that produces tight receptor occupancy even at low plasma concentrations.14 This same property, high-affinity partial agonism, means buprenorphine can displace full agonists from the receptor, precipitating withdrawal if given to a physically dependent patient who has not adequately abstained from full agonists. The clinical management of buprenorphine induction requires careful timing for this reason.14
Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257–1317
doi:10.1124/pr.112.007138Brownstein MJ. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA. 1993;90(12):5391–5393
doi:10.1073/pnas.90.12.5391Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 1975;258(5536):577–580
doi:10.1038/258577a0Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2006;147(Suppl 1):S153–S162
doi:10.1038/sj.bjp.0706435Williams JT, Ingram SL, Henderson G, et al. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013;65(1):223–254
doi:10.1124/pr.112.005942Stein C. Opioid receptors. Annu Rev Med. 2016;67:433–451
doi:10.1146/annurev-med-062613-093100Sia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology. 2008;109(3):520–526
doi:10.1097/ALN.0b013e318182af21Fichna J, Janecka A, Costentin J, Do Rego JC. The endomorphin system and its evolving neurophysiological role. Pharmacol Rev. 2007;59(1):88–123
doi:10.1124/pr.59.1.3Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760–773
doi:10.1016/S2215-0366(16)00104-8Viscusi ER, Webster L, Kuss M, et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain. 2016;157(1):264–272
doi:10.1097/j.pain.0000000000000363Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747–758
doi:10.1093/bja/aen094Coluzzi F, Billeci D, Maggi M, Corona G. Testosterone deficiency in non-cancer opioid-treated patients. J Endocrinol Invest. 2018;41(12):1377–1388
doi:10.1007/s40618-018-0964-3Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150(6):387–395
doi:10.7326/0003-4819-150-6-200903170-00103Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict. 2010;19(1):59–72
doi:10.1111/j.1521-0391.2009.00007.x